Developing a new drug for acromegaly

As we reported earlier this year, the acromegaly new drug development world has seen very exciting activity. Several studies are in the pipeline for oral therapies.  Today, San Diego California based Crinetics Pharmaceuticals announced a new website to encourage patients to join two new studies.

There are two ACROBAT studies, and one of them may be right for you. These studies are conducted at specialized endocrinology centers around the world, including centers in Europe, the United Kingdom, and the United States.

ACROBAT EDGE – is an open label exploratory study to evaluate the safety, pharmacokinetics (the way a drug moves in the body) and efficacy of CRN00808 in patients with acromegaly treated with somatostatin analogue based treatment regimens.

ACROBAT EVOLVE – A double-blind, placebo controlled, randomized (learn about these types of studies here) withdrawal study to evaluate the safety, pharmacokinetics and efficacy of CRN00808 in patients with acromegaly that are responders to octreotide LAR or lanreotide depot.

CRN00808 is a non-peptide, orally bioavailable, somatostatin agonist that is under development for the treatment of acromegaly as an investigational drug.  In an initial Phase 1 clinical trial, once daily CRN0080 administration for up to 10 days was shown to result in IGF-1 lowering in healthy volunteers.  These new Phase 2 studies represent the first time CRN00808 has been studied in acromegaly patients.

You can read more about CRN00808 in the Crinetics website.  Also, you can listen to our podcasts with Dr. Scott Struthers, Crinetics founder and CEO, where he talks about his work at Crinetics and CRN00808.

Go to to learn about the trials; see if you are eligible; learn about study locations; how to help get the word out on this critical work; and much more.


© 2019, Pituitary World News. All rights reserved.